Many therapeutic antibodies use antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) as key mechanisms of action.
Here, we present a method for quantifying ADCP activity based on a novel iLite® effector cell and three genetically engineered target cells expressing a constant high level of the surface antigens CD20, HER2, or mTNF, as well as their antigen-negative counterparts.
Furthermore, by comparing our iLite ADCP assays to ADCP bioassays from a leading competitor, we found that the iLite ADCP assays offer a significantly improved dynamic range, while at the same time offering excellent sensitivity.